Results 91 to 100 of about 311,459 (229)
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard +13 more
wiley +1 more source
Efficacy and Safety of Rituximab in Pediatric Neuromyelitis Optica
Neuromyelitis optica is a central nervous system disease characterized by optic neuritis and transverse myelitis. It is a devastating illness, and early treatment may prevent future relapses and severe disability.
Kenneth Silver +4 more
core +1 more source
Update on neuromyelitis optica: natural history and management
Panitha Jindahra1,2, Gordon T Plant1,21The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK; 2St Thomas' Hospital, Westminster Bridge Road, London, UKAbstract: Neuromyelitis optica or Devic disease is an inflammatory ...
Jindahra P, Plant GT
core
This systematic review evaluated drug‐target Mendelian randomisation studies on periodontitis. Twelve studies identified host‐response‐related targets mainly involved in inflammatory, complement, and immune pathways. Although some targets were linked to existing drugs, the evidence remains preliminary and heterogeneous, requiring replication and ...
Luigi Nibali +4 more
wiley +1 more source
ABSTRACT Purpose To demonstrate the synergy of undersampled radial 2in1‐RARE‐EPI acquisition and nonlinear model‐based reconstruction for accelerated and simultaneous T2, T2*, and R2′ mapping in brains of patients with multiple sclerosis (MS). Methods 2in1‐RARE‐EPI combines a RARE module with an EPI module to capture T2 and T2* information.
Jose Raul Velasquez Vides +16 more
wiley +1 more source
Neuromyelitis Optica Spectrum Disorders: Diagnosis and Treatment
The last decade has witnessed rapid developments in the clinical understanding and scientific foundation of neuromyelitis optica (NMO).curriculum_fellow; IC-E4cii1-relationships-between-optic-neuritis-and-multiple-sclerosis; IC-E4cii3-classification-and ...
Dean M. Wingerchuk, MD, MSc, FRCP(C)
core
Clinical evaluation of rituximab treatment for neuromyelitis optica
Introduction: Neuromyelitis optica is an inflammatory and usually relapsing demyelinating autoimmune disease of the central nervous system that targets the optic nerves and spinal cord. Rituximab has been used for different neurological diseases that are
M.J. Fernández-Megía +5 more
doaj +1 more source
We investigated associations between a panel of diffusion MRI metrics and myelin content, using ViSTa apparent myelin water fraction (aMWF) as a proxy for myelin. Fractional anisotropy (FA) showed a robust association with aMWF; however, more advanced metrics including radial kurtosis (K⊥) and axonal water fraction (f) had stronger correlations ...
Hunter G. Moss +5 more
wiley +1 more source
Neuromyelitis Optica Spectrum Disorder
Over the past 13 years neuromyelitis optica spectrum disorder (NMOSD) has emerged as a discrete form of demyelinating disease of the central nervous system in which antibodies against a water channel found in high concentration on astrocytes are ...
Broadley, Simon +3 more
core
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more [PDF]
B cells and antibodies constitute an important element in different inflammatory diseases of the central nervous system (CNS). Autoantibodies can serve as a biomarker to identify disease subgroups and may in addition contribute to the pathogenic process.
Mayer, Marie Cathrin +5 more
core +1 more source

